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Running head: IRRITABILITY IN HUNTINGTON’S DISEASE 
Validity of irritability in Huntington’s disease: A  scoping review  
Abstract 
Purpose: To scope the literature concerning irritability in Huntington’s disease to determine 
whether or not irritability is a valid and meaningful construct within this population. 
Method: A scoping literature review was conducted based on findings from a search of five 
databases (Academic Search Ultimate, PsycINFO, CINAHL, Scopus and Web of Science) in 
November 2018. From an initial return of 453 papers, 40 were found suitable for review. 
Results: Review of the 40 studies highlighted several aspect  of irritability in people with 
HD which influence its validity as an independent construct in context of the disease. While 
various measures are used to assess irritability, a gold standard has yet to be identified and 
consequently irritability is assessed inconsistently across the literature. In addition, the results 
suggest that irritability may not reflect pathological disease processes in HD, but rather 
comprises a multidimensional construct which appears to be strongly associated with other 
psychological difficulties such as depression and axiety. 
Conclusions: The current concept of irritability in people with HD continues to lack a 
general consensus in the clinical literature, in terms of both operationalisation and 
assessment. Consequently, further research is warranted in order to determine the extent to 
which irritability is a valid construct within the context of HD, including its associated 
behavioural, cognitive and affective dimensions.   


















It has been suggested that irritability is commonly experienced by people with 
neurological conditions such as Parkinson’s disease (PD; Aarsland et al., 1999), dementia 
(Burns, Folstein, Brandt & Folstein, 1990) and progressive supranuclear palsy (PSP; 
Gerstenecker, Duff, Mast, Litvan & ENGENE-PSP Study Group, 2013). However, it is 
perhaps most notably discussed in people with Huntington’s disease (HD; Wagle, Wagle, 
Markova & Berrios, 2000), where it is often reported as an important ‘neuropsychiatric’ 
symptom of the disease process (Klöppel et al., 2010). Nonetheless, while many studies have 
reported high rates of irritability in people with HD (Craufurd, Thompson & Snowden, 2001; 
van Duijn, Kingma & van der Mast, 2007), it has been argued that the current 
conceptualisations lack psychological rigour, suggesting that research on and measures of 
‘irritability’ could in fact be potentially measuring different concepts, for example anger and 
aggression (Craig, Heitanen, Markova & Berrios, 2008).   
 
Introduction to Huntington’s disease 
 
HD is an inherited neurodegenerative disease, caused by an autosomal-dominant 
mutation of a gene located on the short arm of chromosome 4, and characterised by a triad of 
progressive difficulties in motor, cognitive and behavioural domains (Craufurd et al., 2001). 
Formal diagnosis of HD is made when motor symptoms become apparent (Tabrizi et al., 
2009), which usually occurs around the age of 40 with the disease subsequently progressing 
over 15-20 years (Novak & Tabrizi, 2010). However, psychological and cognitive difficulties 
are frequently experienced by people carrying the mutated gene (often referred to as ‘gene 
positive’ or ‘presymptomatic HD’) prior to motor symptom onset (Duff et al., 2007; Roos, 


















irritability, depression and anxiety argued to form the three core psychological difficulties 




Irritability is generally characterised as a readiness to react excessively to negative 
stimuli, often having both an affective component (anger) and behavioural component 
(aggression) (Buss & Durkee, 1957; Caprara et al., 1985). However, it is ill-defined and 
sometimes, as a concept, not effectively rooted in psychological theory. For example, Snaith 
and Taylor (1985) proposed a definition of irritability as a “feeling state characterised by 
reduced control over temper which usually results in irascible verbal or behavioural 
outbursts, although the mood may be present without observed manifestation” (p.128); 
likewise Paoli et al. (2017) defined irritability as “a temporary psychological state 
characterized by impatience, intolerance, and poorly controlled anger” (p.6). These 
definitions are inconsistent with psychological theory which differentiates between an 
emotion and a mood, seeing them as closely related yet istinct phenomena on the grounds of 
characteristics such as duration, apparent cause, intentionality, consequences and function 
(Beedie, Terry & Lane, 2005). 
Craig et al. (2008) instead conceptualised irritability as a more prolonged mood state, 
differentiating it from emotions such as anger (which tend to be more reactive and short-
lived). Snaith and Taylor (1985) examined irritability in clinical populations across four 
studies, including people experiencing depression, anxiety, mood disorder and obsessional 
neurosis, which also indicated that irritability should be understood as a mood state rather 


















 Conversely, irritability has also been conceptualised as a stable personality trait (Buss 
& Durkee, 1957). For example, early German psychopathologists referred to changes in 
behaviour, such as irritability, as part of personality change (Craufurd & Snowden, 2014). It 
is evident that there are opposing views as to whether irritability should be conceptualised as 
a state or trait (Burns et al., 1990), or a further possibility may be that it has elements of both.  
Specifically in terms of people with HD, irritability has been conceptualised using the 
definitions applied to the general population. However, its occurrence within this population 
can be more difficult to determine due to the brain changes associated with the condition, 
potential differences in understandings of irritability and a lack of reliable methods of 
assessment (Craufurd & Snowden, 2014). 
 
Causes of irritability in people with HD  
  
Various explanations have been advanced regarding the cause of irritability in people 
with HD (Craufurd & Snowden, 2014). Irritability iscommonly viewed as the result of the 
biological progressive neurodegenerative nature of the disease. Indeed, it has been suggested 
that higher levels of irritability in people with HD, compared with spouse controls in the 
same environment, “implicates a neurobiological, rather than psychological or reactive, basis 
for these behavioural signs” (Tabrizi et al., 2009, p.799). For example, it has been suggested 
that degeneration in brain regions that control socially appropriate behaviour, such as the 
prefrontal area, may result in irritability in the earlier stages of HD (Mega & Cummings, 
1994). This is consistent with wider understandings that neurodegenerative changes in people 
with HD are important in the development of all psychological difficulties experienced by 
people with the condition, in which irritability and aggressiveness are at the forefront, 


















However, while irritability is frequently identified as a primary difficulty experienced 
by people with HD, some authors theorise that it may be secondary to other psychological 
difficulties such as depression (Craufurd & Snowden, 2014; van Duijn., 2010). Furthermore, 
some affected individuals report experiencing suicidal deation after episodes of heightened 
irritability (Craufurd & Snowden, 2002), indicating a potential association between irritability 
and suicidality. Irritability may, at least in part, also be a consequence of experiencing 
frustration with increasingly difficult communication and cognition (Craufurd & Snowden, 
2014). Indeed, although the dominant understanding is biologically-based, behaviour in 
people with HD is also likely to reflect both intrinsic and reactive changes (Craufurd & 
Snowden, 2014).   
 
Validity of irritability  
 
  Several types of assessment have been argued to b important in terms of 
establishing whether a construct is valid and therefore construct validity, which can be 
conceptualised as a superordinate level of validity, and is often seen as the most difficult type 
of validity to achieve. Indeed, it can also only be demonstrated when more specific elements 
of validity have been established, e.g., convergent validity which refers to the degree to 
which a construct is similar to another construct to which it should be similar (Kendal, 1975).   
Due to the lack of consensus around the construct and v lidity of irritability as it 
specifically presents in people with HD, it is timely to review the empirical evidence. 
Irritability is one of the key psychological difficulties considered important to treat in people 
with HD, so it is essential that therapeutic approaches are enabled to target a construct which 
is clear, defined and widely understood to be the same across studies and measures. A 


















findings from the research. This is suitable for the assessment of construct validity, which is a 
broader aim than would be typical for a conventional systematic review where the review is 
focused on a narrower and more specific question. Csequently, this review will answer the 
question: what is the current conceptualisation of irritability among people with HD? It will 
also be considered whether the current conceptualisation is valid and clinically meaningful. 
 
Previous reviews  
Three prior reviews have been conducted in this general area, although none focusing on this 
or a similar question. Ramos and Garrett (2017) reviewed symptoms specifically associated 
with the premotor phase, concluding that irritability is overall increased in this phase 
compared to non-carriers. Honrath et al. (2018) systematically reviewed evidence for a link 
between irritability and suicidal ideation, finding poor evidence of any connection from prior 
studies. Finally, Dale and van Duijn (2015) reviewed evidence for associations between 
anxiety and irritability in people with HD, finding that those with the condition who have 
higher levels of anxiety may be more prone to becoming irritable. Although there is therefore 
evidence pertaining to irritability in people with HD in existing reviews, no review has 
focused explicitly on the construct of irritability or its validity. This review will therefore be 




 A scoping review approach was adopting, following the stages outlined by Arksey 
and O’Malley (2005). Studies appropriate for inclusion were selected and the relevant data 


















inclusion met the following criteria: (i) published in English; (ii) published in a peer-
reviewed journal; (iii) involved the investigation f irritability in people with a verified 
presence of the HD gene (both symptomatic and presymptomatic), including prevalence, 
associations with other variables, treatment options a d aetiology. Papers investigating 
irritability in mixed samples of people with HD and other neurological conditions were 
excluded if the authors did not report findings for each condition separately. 
Relevant papers were identified by searches of the databases Academic Search 
Ultimate (searchable from 2002, ‘peer reviewed’ and‘English’ selected), PsycINFO 
(searchable from 1940, ‘peer reviewed’ and ‘English’ selected), CINAHL (searchable from 
1999, ‘peer reviewed’ selected), Scopus (searchable from 2006, ‘English’ and ‘Journals’ 
selected), and Web of Science (searchable from 1990). The search was conducted in 
November 2018, and the search terms used to identify potential papers were “irritability” and 
“Huntington*”. This database search returned 453 papers (Academic Search Ultimate = 50, 
PsycINFO = 78, CINAHL = 12, Scopus = 213 and Web of Science = 100). Duplicates were 
removed and the remaining papers were reviewed for suitability by screening titles and 
abstracts. Review papers, commentaries and case studi s were excluded. For papers where 
eligibility was unclear, the full text was reviewed. References of included papers were also 
searched for relevant studies, although none were located which had not been identified on 
database search. Ultimately, 40 papers were identifi d as suitable for inclusion in the current 
review. Table 1 provides a summary of key characteristics of the included studies, and Figure 
1 details the paper selection process. As quality appraisal is not considered a requirement for 
scoping reviews (Arksey & O’Malley, 2005), this was not conducted. Although some reviews 
in the field of HD (e.g. Crozier, Robertson & Dale, 2015; Dale & van Duijn, 2015) exclude 
papers published before 1993 due to the predictive test not being available until then 


















parameters on the basis that this might exclude paprs which did confirm genetic status on an 
individual study basis. However, only two papers were found which were published before 
1993. In the Burns et al. (1990) paper, the HD sample is described as positive gene carriers, 
and in the Pflanz et al. (1991) paper as patients whom the clinician in charge was confident of 
their diagnosis of HD based on clinical presentation.  
(<Insert Table 1 and Figure 1 here>) 
Results 
  
Forty papers were included in the current scoping review; the relevant results are 
summarised in Table 2. Of the 40 papers, 12 compare irritability in people with HD to 
healthy controls, 12 examine changes in irritability across disease stage, two compare 
irritability in individuals with HD with those with other neurological conditions, 17 report 
associations with other psychological difficulties n people with HD, three describe 
interventions and four report potential neurological pathways for irritability in HD. In 
addition, the measures used to assess irritability are discussed. 
(<Insert Table 2 here>) 
Measures of irritability 
 
A wide range of measures were used in the reviewed studies to assess irritability in 
people with HD (see Table 3). Eleven studies used th  behavioural component of the United 
Huntington’s Disease Rating Scale (UHDRS; Anderson et al., 2016; Banaszkiewicz et al., 
2012; Craufurd et al., 2001; Hubers et al., 2013; Reedeker et al., 2012; Rickards et al., 2010; 
Thompson et al., 2002; van Duijn et al., 2014; van Duijn et al., 2018; Vassos, Panas, Kladi & 


















(PBA; Craufurd et al., 2001; Gregory et al., 2015; Kingma et al., 2008; Reedeker et al., 2012; 
Thompson et al., 2002; Thompson et al., 2012; van Duijn et al., 2013; van den Stock et al., 
2015), one its Dutch equivalent (NL-PBA; Bouwens et al., 2016), and four the PBA short-
form (PBA-s; Fritz et al., 2018; Honrath et al., 2018; Martinez-Horta et al., 2016; Ruiz-Idiago 
et al., 2017). Three studies used the Irritability Scale (IS; Bouwens et al., 2015; Diago et al., 
2018; Reedeker et al., 2012), four used the Snaith Irr ability Scale (SIS; Berrios et al., 2001; 
2002; Klöppel et al., 2010; Maltby et al., 2016) and two the Hospital Anxiety and Depression 
Scale combined with the SIS (HADS-SIS; Underwood et al., 2016; Vassos et al., 2007). Two 
used the Irritability, Depression, Anxiety Scale (Nimmagadda et al., 2011; Singh-Bains et al., 
2016), two the John Hopkins Irritability Questionnaire (JHIQ; Chatterjee et al., 2005; 
Klöppel et al., 2010), two the abbreviated Minnesota Multiphasic Personality Inventory 
irritability scale (MMPI; Kirkwood et al., 2002a; 2002b), and two the Neuropsychiatric 
Inventory (NPI; Litvan, Paulsen, Mega and Cummings, 1998; Paulsen, Ready, Hamilton, 
Mega & Cummings, 2001). One study each used the Barratt Impulsiveness Scale (BIS; 
Nimmagadda et al., 2011), the Present State Examination (Pflanz et al., 1991), the Hostility & 
Direction of Hostility Questionnaire (HDHQ; Vassos et al., 2007), the Composite 
International Diagnostic Interview (CIDI; Julien et al., 2007) and Burns et al. (1990) 
developed a bespoke Irritability/Apathy Scale for their study. 
The IDAS (Snaith et al., 1978) was initially developed to address the need for scales 
to assess irritability in clinical populations, and has been used in studies assessing irritability 
in people with HD (Berrios et al., 2001; Berrios et al., 2002; Nimmagadda, Agrawal, Worrall-
Davies, Markova & Rickards, 2011). Snaith et al. described irritability as a two-dimensional 
construct, which led to an elaboration of the IDAS into two subscales measuring outwardly- 
and inwardly-expressed irritability (Snaith & Taylor, 1985); these may correspond to the 


















to Ruiz-Idiago et al. (2017). Snaith and Taylor’s self-report measure assesses subjective 
irritability. Snaith and Taylor’s interpretation was somewhat supported on factor analysis of 
the Snaith Irritability Scale by Maltby et al. (2016), who found two equally well-fitting 
bifactor models representing the data. Bifactor models explain data via joint explanations, a 
single general factor (in this case “irritability”) which explains the shared variance of all 
items, and individual (“group”) factors which each explain some of the variance too, but 
allow recognition of multidimensionality within the data. Maltby et al. found justification for 
Snaith and Taylor’s interpretation (outwardly- and i ward-expressed irritability, alongside the 
irritability general factor)) but also for another bifactor model in which “temper” and “self-
harm” were the group factors. Importantly, both models showed higher loadings for items for 
the general factor, and the general factor explained more variance; the authors therefore 
recommended that the full-scale score should be used a  the overall measure of irritability, 
rather than generating sub-scales. This may have implications for the validity of studies 
which rely on the sub-scales, such as Singh-Bains et al. (2016), who used the outward 
irritability component of the IDAS as a measure of irritability when exploring the role of 
globus pallidus degeneration in HD.  
The PBA is a semi-structured interview used with both people with HD and close others such 
as family members. The scale comprises three factors (apathy, irritability and depression), all 
with individual sub-scale items (for example on obsessions/perseverative thinking and psychosis) 
and includes ratings from patients and informants, as well as observations from clinicians, 
thereby encompassing multiple perspectives. Irritabil y items include inflexibility, 
preoccupations, irritability, and verbal and physical aggression (Craufurd et al., 2001). Items 
are reported on five-point scales to assess both the frequency and severity of behavioural 
difficulties, and multiplied for an overall score (Gregory et al., 2015). The short-form PBA-s 


















original PBA on principal components analysis, as well as equivalent good inter-rater 
agreement (Callaghan et al., 2015). 
 (<Insert Table 3 here>) 
Further measures that have been used to assess irritabil ty in people with HD include 
the behavioural section of the Unified Huntington’s Di ease Rating Scale (UHDRS-b) and 
informant-report measures such as the John Hopkins Irr tability Scale and the Burns 
Irritability Scale (BIS; Burns et al., 1990). The Unified Huntington’s Disease Rating Scale 
(UHDRS; Huntington Study Group, 1996) is one of the most commonly-used measures, 
assessing motor, cognitive and behavioural aspects of HD as well as functional capacity; it 
was used in a number of studies included in the current eview (Banaszkiewicz et al., 2012; 
Hubers et al., 2013; Reedeker et al., 2012; Rickards et al., 2011; Thompson, Snowden, 
Craufurd & Neary, 2002; van Duijn et al., 2014). The BIS also purports to allow an objective 
measure of irritability to be obtained from a carer or family member, aiming to measure a 
change in behaviour in the context of illness rather an objective irritability level, i.e. 
someone who has always been irritable would be unlikely to score highly for irritability using 
this scale. 
The present results suggest that measures differ in the r conceptualisation and 
measurement of irritability. Although multi-item irritability measures such as the Irritability 
Questionnaire have been shown to have good reliability and assess various thoughts, feelings 
and behaviours related to irritability, scales attempting to measure irritability also tap into 
constructs such as anger and hostility (Holtzman, O’Connor, Barata & Stewart, 2015). This 
may be problematic in the assessment of irritability since irritability, unlike anger, often 
occurs in the absence of a direct antecedent and lasts longer, suggesting that they are different 


















2008). Nonetheless, despite it being generally acknowledged that irritability is distinct from 
anger and aggression, this is not currently reflected in the measures used to assess it 
(Holtzman et al., 2015). 
 
Irritability in people with HD compared with health y controls 
 
Thirteen studies have compared irritability in peopl  with HD with healthy controls 
(Anderson et al., 2016; Berrios et al., 2001; Berrios et al., 2002; Diago et al., 2018; Julien et 
al., 2007; Kirkwood et al., 2002a; Kirkwood et al., 2002b; Kingma, van Duijn, Tinman, van 
der Mast & Roos, 2008; Klöppel et al., 2010; Martinez-Horta et al., 2016; Reedeker et al., 
2012; van den Stock et al., 2015; Vassos et al., 2007). Seven of these studies found that 
irritability is significantly higher in people with HD compared with non-carrier controls 
(Berrios et al., 2001; Berrios et al., 2002; Julien et al., 2007; Kingma et al., 2008; Kirkwood 
et al., 2002a; Reedeker et al., 2012; van den Stock et al., 2015). Additionally, Martinez-Horta 
et al.’s (2016) examination included presymptomatic individuals not long prior to onset and 
found that both this group and those with early-stage HD had significantly higher irritability 
than non-carrier controls, indicating that changes in irritability pre-empt motor onset. In 
addition, Kirkwood et al. (2002a) observed an increase in irritability and clinical hostility 
over an average of 3.7 years in pre-symptomatic gene carriers compared with non-gene 
carriers. Similarly, Berrios et al. (2002) found that gene carriers had significantly higher 
inward and outward irritability than non-gene carriers measured by the SIS, which was 
suggested to be a possible result of irritability being part of a personality change occurring as 
a consequence of HD – importantly, the authors selected participants prior to genetic testing, 


















that irritability may develop/increase prior to the occurrence of clinical motor symptoms, and 
in general that irritability is a clinical feature across the disease course. 
However, four of the 12 studies which compared people with HD to healthy controls 
failed to find a significant between-group differenc  in irritability (Diago et al., 2018; 
Kirkwood et al., 2002b; Klöppel et al., 2010; Vasso et al., 2007). Klöppel et al. (2010) also 
did not find a significant difference between pre-symptomatic gene carriers and non-gene 
carriers. Additionally, there was good agreement betwe n pre-symptomatic gene carriers and 
their close companions regarding their level of irritability, suggesting that lowered insight 
into irritability as reported by Reedecker et al. (2012) may occur later in the disease process. 
Similarly to Klöppel et al. (2010), Kirkwood et al. (2002b) did not find a difference in 
irritability between those with manifest HD, pre-symptomatic gene carriers and non-gene 
carriers as measured by the MMPI. However, although the MMPI measures personality traits 
and psychopathology, it may not be sensitive to changes in people with HD because it has 
never been standardised for this population. Nevertheless, the use of the SIS (which was 
constructed for use with clinical populations) was also unable to detect differences in 
irritability between pre-symptomatic gene carriers and non-gene carriers (Klöppel et al., 
2010). The choice of measure is therefore likely to represent only one of several variables 
which may have contributed to the lack of significant results.  
Finally, Vassos et al. (2007) investigated the psychological and behavioural features 
which differentiate people with HD from non-affected individuals, and did not find a 
significant difference in either inward or outward i ritability as measured by the SIS. The 
authors reported a small effect size of d = 0.20 for inward irritability, which suggests an 
effect is potentially detectable, but reported d = 0.06 for outward irritability, suggesting there 


















significantly higher level of extroverted hostility compared with healthy controls, describing 
hostility as a personality dimension rather than a behavioural aspect. Similarly, Berrios et al. 
(2002) found that both inward and outward irritability oaded onto a personality factor for 
people with HD within their derived factor structure (inward irritability did not load on any 
factor for non-carriers), suggesting a qualitative difference in the nature of irritability in 
people with HD.. Finally, Anderson et al. (2016) reported that for non-carriers, irritability 
was significantly predictive of suicidal ideation whereas in gene carriers it was not, 
suggesting that irritability may interact differently with other psychological variables in 
people with the HD gene compared to those without. 
Irritability across disease stage 
 
In addition to comparisons between gene carriers and healthy controls, studies have 
explored whether irritability varies across stage of disease.   Of the 12 papers comparing 
irritability across disease stage, eight did not find significant differences (Bouwens et al., 
2015; Craufurd et al., 2001; Julien et al., 2007; Kingma et al., 2008; Kirkwood et al., 2002b; 
Pflanz, Besson, Ebmeier & Simpson, 1991; Ruiz-Idiago et al., 2017; van Duijn et al., 2013). 
Six were cross-sectional studies, and two longitudinal. The latter found no significant 
increase in irritability between baseline and two-year follow-up (Bouwens et al., 2015; van 
Duijn et al., 2013). Bouwens et al. (2015) measured irritability at two time points using the 
Irritability Scale (Chatterjee, Anderson, Moskoqitz, Hauser & Marder, 2005) and found that 
of those who were irritable at baseline (33%), 70% remained irritable at follow-up two years 
later. Furthermore, of those who were not irritable at baseline, only 23% went on to report 
irritability at follow-up, so overall only minor differences were apparent over the two-year 
period. van Duijn et al. (2013) additionally reported no difference in irritability at two-year 


















Interestingly, although Craufurd et al. (2001) also identified a lack of linear 
relationship between irritability and disease duration, they did find a less straightforward 
relationship. Across their cohort’s disease duration span of 1-23 years, the authors found that 
difficulties defined under the factor ‘irritability’ (including irritability, verbal aggression, 
physical aggression, inflexibility and pathologic preoccupation) occurred more frequently in 
people with a disease duration of 6-11 years, suggesting that disease stage and irritability may 
indeed be related, but in a more complex manner. Collectively, however, these studies 
suggest that irritability does not appear to be dirctly associated with disease stage, and 
therefore may not be an underlying process associated with pathological manifestations of 
HD. 
Conversely, however, three papers identified a difference in irritability across disease 
stage (Gregory et al., 2015; Thompson et al., 2012; van Duijn et al., 2014), although their 
findings were inconsistent. Gregory et al. (2015) found that irritability was significantly 
higher in those with clinically-diagnosed early HD compared with pre-manifest HD, although 
this research was not extended to those with more advanced HD. Martinez-Horta et al. (2016) 
also reported significantly increased risk and preval nce of irritability in groups less than 10.8 
years prior to predicted onset or in the early stages of HD, in comparison to those further 
from predicted onset, although the very broad timespan reduces the generalisability of this 
information and the validity of describing those ten years from becoming symptomatic as 
“close to onset” might also be questioned. van Duijn et al. (2014) additionally found 
moderate to severe irritability (using the behavioural component of the UHDRS) increased by 
stage of disease from 10.4% at stage one (diagnosed, but remaining fully functional) to 
19.6% at stages four and five (advanced stages); however, this increase at such advanced 


















distress due to the increasing impact of HD, and therefore a by-product of other symptoms of 
HD rather than a direct symptom.  
In addition to studies finding a difference in irritability measures between disease 
stages, Honrath et al. (2018) found that irritability has predictive value regarding suicidal 
ideation in manifest but not premanifest groups, with premanifest groups more affected by 
functional changes in activities of daily living, whereas psychological difficulties such as 
irritability were of more relevance in the manifest group. This suggests a change in the 
impact and role of irritability as HD progresses.  
Similarly, a longitudinal study by Thompson et al. (2012) showed an increase in the 
presence of irritability (determined as a score of two or greater for severity) over time as 
measured by the PBA-HD. However, this was limited to a significant linear effect in those 
who entered the study at stage one and two, and not in those who entered at stage three. The 
progression of irritability was therefore only evident in early-stage HD. There may, however, 
be a confound in their measurements; the authors note that irritability was common among 
their sample, describing poor temper control in 80% of participants and physical aggression 
in 50%. While temper and aggression are frequently measured independently of irritability, in 
this study they were assumed to be aspects of irritability as opposed to separate constructs. 
This may have influenced findings, and reduces comparability with other studies in the area.  
Two final studies found decreases in irritability associated with markers of disease 
stage. Although they did not assess disease stage directly, Yang et al. (2016) evaluated 
correlations between irritability and CAG repeats (the extent of the genetic mutation, 
corresponding to the number of trinucleotide repeats on the chromosome)/age of onset in 
Chinese patients, finding that later onset and fewer CAG repeats correlated with lower 


















increasing years since onset despite cognitive and motor deterioration, possibly implying 
some stabilisation of irritability with advancing ae. Therefore, the relationship between 
irritability and age or disease stage overall seems l ss than clear-cut. 
When interpreting these findings, consideration should be given to studies in which 
participants were taking medication to manage their irritability and the impact this may have 
had on its assessment. Participants in Thompson et al.’s (2012) study had access to 
psychiatric input, and therefore may have been taking medication to manage their irritability; 
the increase in irritability only being seen in theearly stages may therefore mean that people 
were prescribed medication when it started to impact on their quality of life. For example, 
Craufurd et al. (2001) reported 35% of participants to be taking medication to manage 
irritability. This might also explain the decrease in irritability as the disease progressed, 
reported by Yang et al (2016) and Singh-Bains et al. (2016). Consequently, differences in 
findings across studies may be influenced by current t atment options being accessed by 
participants.  
 
Comparing HD with other neurodegenerative conditions 
 
Since irritability has been reported to occur in neurological conditions other than HD, 
it is appropriate to compare irritability in this po ulation with other neurodegenerative 
conditions. Burns et al. (1990) compared people with HD with people with Alzheimer’s 
disease (AD) on irritability and apathy using an irritability/apathy scale developed 
specifically for their research, finding no significant difference in irritability between the two 
groups. However, the HD group showed significantly higher levels of aggressiveness than the 
AD group, and their aggressive outbursts lasted significantly longer. Importantly, in both 


















increase in one would not predict changes in the otrs. Interestingly, irritability correlated 
positively with bad temper in the HD group while there was no correlation in the AD group, 
implying that the presentation of irritability and related constructs may differ between 
neurodegenerative conditions. Thus, while there was no ignificant difference between the 
two groups, people with HD demonstrated higher levels of aggression and bad temper than 
those with AD.       
In addition, Litvan et al. (1998) compared people with HD to people with progressive 
supranuclear palsy (PSP) using the Neuropsychiatric Inventory (NPI). Irritability was shown 
to influence the total NPI score in people with HD; additionally, the HD group scored 
significantly higher on agitation, irritability and anxiety, while those with PSP scored higher 
for apathy. In the HD group, agitation was positively correlated with anxiety, irritability, 
disinhibition and euphoria. Similarly, irritability was associated with anxiety, disinhibition, 
euphoria and depression. Logistic regressions indicated that people with HD were more likely 
to exhibit hyperactive behaviour (agitation, irritability) whereas people with PSP were more 
likely to exhibit hypoactive behaviour (apathy). These results are consistent with the findings 
of Burns et al. (1990), who reported that irritability and apathy can occur independently of 
each other. The research in this area is therefore limit d, but there appear to be important 
differences in psychological presentation between HD and other neurodegenerative 
conditions. 
Association with other psychological difficulties  
 
Irritability has also often been investigated along with other psychological difficulties 
reported to be common in people with HD. Of the 17 studies comparing irritability with other 


















2015; Bouwens et al., 2016; Burns et al., 1990; Diago et al., 2018; Fritz et al., 2018; Honrath 
et al., 2018; Hubers et al., 2013; Litvan et al., 1998; Nimmagadda et al., 2011; Paulsen et al., 
2001; Pflanz et al., 1991; Thompson et al., 2002; Underwood et al., 2016; van Duijn et al., 
2014; van Duijn et al., 2018), nine reported correlations between irritability and other 
psychological difficulties, and one reported association via multiple regression. Nine of these 
studies reported significantly positive correlations with other psychological difficulties 
including apathy (Bouwens et al., 2015; Pflanz et al., 1991), anxiety (Litvan et al., 1998; 
Nimmagadda et al., 2011; Paulsen et al., 2001), depression (Litvan et al., 1998; Nimmagadda 
et al., 2011; van Duijn et al., 2014), bad temper (Burns et al., 1990) and suicidal ideation 
and/or behaviour (Anderson et al., 2016; van Duijn et al., 2018). Fritz et al. (2018) 
additionally identified that poorer behavioural scores (a composite score from the PBA-HD 
short form, covering ten behavioural problems including irritability, although not a specific 
measure of irritability in itself) were associated with higher apathy scores (large effect size: 
R2 = 0.30), in line with research specifically examining irritability as a stand-alone variable. 
A single paper reported no correlation between irritability and cognitive impairment 
(Thompson et al., 2002). 
In addition to the van Duijn et al. (2018) study of suicidal ideation and behaviour, 
which found moderate/severe irritability to be modestly predictive of both, Hubers et al. 
(2013) found irritability was significantly positively correlated with suicidal ideation at 
baseline. However, this was not maintained at four-year follow up and thus irritability was 
not considered an independent predictor of suicidal ideation. It should though be considered 
that since the cohort were all four years further into the disease course by follow-up, it should 
be considered that the predictive value of irritability may relate to disease stage. A further 
study by Honrath et al. (2018) found that irritability significantly predicted suicidal ideation 


















In a study of apathy and irritability, Bouwens et al.’s (2015) longitudinal analysis 
demonstrated that an increase in irritability was as ociated with an increase in apathy over a 
two-year period, an association which was maintained after confounds such as age, sex, 
motor function change and medication use had been controlled. Although the concomitant 
increase in apathy and irritability appears paradoxical, the authors suggested that while 
irritability is often linked to the outward expression of anger, it may also be expressed and 
experienced internally (similar to Snaith and Taylor’s (1985) development of the IDA to 
examine both inward and outward irritability), and therefore some people with HD may 
experience inward irritability alongside external apathy. Consequently, apathy has the 
potential to mask irritability by limiting overt expression. 
 Furthermore, three studies found associations between irritability and anxiety. Both 
Litvan et al. (1998) and Paulsen et al. (2001) found irritability to be significantly positively 
correlated with anxiety (r = 0.88 and r = 0.43 respectively), as measured by the NPI.  
Similarly, Nimmagadda et al. (2011) found that participants’ inward and outward irritability 
scores were both significantly positively associated with both their state and trait anxiety, as 
measured by the IDAS and State-Trait Anxiety Inventory. While a causal relationship cannot 
be determined, irritability could hypothetically occur in response to feelings of anxiety.  
Therefore, people with HD who have higher levels of anxiety may be more prone to 
becoming irritable.  
 In addition to apathy and anxiety, there were alsossociations between irritability and 
depression. Irritability was found to be positively correlated with depression in Litvan et al.’s 
(1998) study using the NPI, and Nimmagadda et al. (2011) found irritability (both IDAS-
inward and IDAS-outward) to be significantly positively associated with depression as 


















Depression Rating Scale (MADRS). However, these correlations did not persist when 
irritability was informant-reported on the Barratt Impulsiveness Scale. The authors suggest 
that this could be due to informants not recognising irritability in people with HD struggling 
with depression, which is supported by the IDA-inward irritability score showing a stronger 
correlation with the depression score on the MADRS, suggesting that people experiencing 
depression in HD may internalise irritability and thus hide it from those around them. 
Interestingly, evidence suggests that a history of depression (van Duijn et al., 2014) and bad 
temper (Burns et al., 1990) may increase the likelihood of people with HD experiencing 
irritability. In contradiction to the above studies, however, van Duijn et al. (2018) found only 
a weak correlation between depressed mood and irritability, although both were 
independently predictive of suicidal ideation/behaviour in their study. 
In terms of associations between irritability and more functional HD symptoms and 
characteristics, Banaszkiewicz et al. (2012) found that irritability was not significantly related 
to functional disability, Bouwens et al. (2016) found no relation between plasma cytokine 
levels and irritability (although there was a significant association between plasma cytokine 
levels and executive function) and Diago et al. (2018) found that although markers of poor 
sleep quality moderately correlated with irritability, these trends were non-significant. 
Additionally, Underwood et al. (2016) noted that interviewer-rated irritability positively 
predicted likelihood of severe pain, although greater participant-rated irritability did not 
(despite participant-rated measures of anxiety and depression being significant predictors). 




















Treatment options for irritability in people with H D 
 
 Three papers examined the treatment options for irritability in people with HD 
(Bouwens et al., 2015; Groves et al., 2011; van Duijn, 2010). Groves et al. (2011) used an 
HD irritability survey developed specifically for their research, which revealed use of various 
pharmacological treatments to reduce irritability with little general consensus, particularly 
with regards to treatment duration (although there was some agreement among expert 
clinicians regarding selective serotonin reuptake inhibitors (SSRIs) and antipsychotics 
(APDs) being the preferred medication). Additionally, when considering that people with HD 
may also experience other psychological difficulties, medication choice was affected by 
reported psychological comorbidities. SSRIs were prefer ed when irritability occurred with 
comorbid depression and anxiety, whereas APDs were often used when irritability occurred 
alongside aggression and impulsivity (suggesting that i  may be used to treat these comorbid 
difficulties, not the irritability itself).   
 Given the difference in usage by clinicians, it is possible that the medication used may 
actually be affecting the comorbid psychological difficulty, e.g. depression, as opposed to 
irritability; the treatment of such co-occurring difficulties may in fact be more effective than 
targeting irritability. Consequently, it could be suggested that irritability occurs as part of 
these associated psychological difficulties, i.e. depression and anxiety, rather than 
representing a valid individual ‘symptom’ of HD. 
 Interestingly, Bouwens et al. (2015), in a longitud nal study, found that the use of 
APDs was associated with an increase in irritability over a two-year period. However, it 
cannot be ruled out that APDs were prescribed when irritability presented and were therefore 
an active treatment while irritability increased due to another process, rather than the 


















 It is also worth noting the general increased incidence of medication associated with 
irritability; Martinez-Horta et al. (2016) reported strong positive correlations between 
irritability and use of antidepressants, benzodiazepines and neuroleptics, although since 
reason for prescription or associated tracking of symptoms was not provided, this is not 
informative regarding the helpfulness of medication. It is clinically useful however to be 
aware of the apparent tendency towards prescription of medication in those with increased 
irritability, and to consider the justification and potential risks/benefits in patient care. 
 
Suggested neurological pathways for irritability in people with HD 
 
 Little is known about the potential neurological changes associated with the 
psychological aspects of HD. Four relevant studies have been conducted (Gregory et al., 
2015; Klöppel et al., 2010; Singh-Bains et al., 2016; van den Stock et al., 2015) 
 van den Stock et al. (2015) found evidence of striatal atrophy and increased irritability 
in the gene positive group compared to healthy controls. The authors evaluated the 
association between clinical irritability and experience of anger by correlating irritability 
scores on the PBA-HD with functional magnetic resonance imaging (fMRI) activation in 
people who were gene positive, but not showing motor symptoms. A significant positive 
correlation was identified between irritability and pulvinar activation, implying that the 
thalamic pulvinar plays a key role in irritability in HD. Additionally, anger experience was 
associated with hyper-activation of the emotion experience neurocircuitry. It is important to 
differentiate between brain activation relating to anger and irritability, as these appear to be at 
least partially separate. Importantly, research in other conditions have implicated striatal and 
orbitofrontal-subcortical circuit deterioration in the development of socially inappropriate 


















argue may also be the case in people with HD; van den Stock’s (2015) study of striatal 
atrophy may support this to a degree. 
 Klöppel et al. (2010) found higher levels of reported irritation were associated with 
stronger amygdala activation in controls compared to pre-symptomatic gene carriers, for 
whom equivalent correlational analyses were non-sigificant. The authors argue that 
inappropriate responses of the amygdala make pre-symptomatic gene carriers increasingly 
prone to psychological difficulties such as irritablity. Additionally, the involvement of the 
amygdala has been highlighted in the experience of negative emotions such as irritability 
(e.g. Leibenluft, 2017), anger (e.g. Reuter, Weber, Fiebach, Elger & Montag, 2009) and 
frustration (e.g. Yu, Mobbs, Seymour, Rowe & Calder, 2014) more generally as opposed to 
being specific to irritability. 
 Furthermore, comparing people with early-stage HD with pre-manifest HD, Gregory 
et al. (2015) found a significant correlation between irritability (measured by the PBA-HD) 
and a decrease in white matter microstructure across the whole brain (identified via fractional 
anisotropy). These findings were reversed in those closer to onset, with results maintained 
following controlling for medication use. Additionally, the authors suggested that due to the 
dominant involvement of the posterior tracts and left h misphere, it is possible that the 
increase in irritability could result from cognitive overload.  
 Finally, Singh-Bains et al. (2016) found that deterioration in the internal subsection of 
the globus pallidus was significantly correlated with decreasing irritability in their small-
sample study relating post-mortem neurological findings to clinical symptom scores. The 
authors hypothesise that irritability occurs in theearly stages of HD (as also found by 
Thompson et al. (2012)) and subsequently stabilises, either due to a natural change over the 


















associated with reduced irritability) or because medication or other management strategies 
mitigate irritability over time (Scher & Kocsis, 2012). However, no hypothesis relating 
specifically to neurodegeneration in this region was suggested. Overall, the evidence 
regarding how neural changes may relate to irritabil y in people with HD seems unclear, and 
potentially confounded by other psychological and cognitive factors.  
Discussion 
 
One of the prime difficulties with research into irritability is measurement, as 
indicated by the wide range of prevalence reported in different studies. For example, van 
Duijn et al.’s (2007) review found reported rates of irritability in people with HD to range 
from 38% to 73% as measured by the PBA-HD and NPI. Indeed, considering that there is no 
gold standard for measuring irritability, cut-off scores between studies vary somewhat and 
are essentially arbitrary (Reedeker et al., 2012), leaving potential for different results. For 
example, three studies using the Irritability Scale (Chatterjee et al., 2005; Klöppel et al., 
2010; Reedeker et al., 2012) used varying cut off scores of >15 and >14. Statistically, there is 
also a loss of sensitivity when assessments above and below cut-off are compared; it is 
preferable to use continuous variables where possible, which many studies did not (Altman & 
Royston, 2006). While efforts have been made to reduce the impact of varying cut-offs on 
findings, it seems that if irritability is to be considered a symptom of HD, standardised 
measures and scores specific for people with HD are ess ntial. However, this highlights a 
vicious circle; difficulties with agreement regarding standardised measures and clinical cut-
off scores are perpetuated by the lack of agreed definition, which inhibits the ability to 
designate clinically valid cut-off scores.  
In addition, there remains no gold standard for asses ing irritability (Bouwens, van 


















assess irritability both in non-HD and HD populations, for example, the Buss-Durkee 
Hostility Inventory (BDHI) and the Problem Behaviours Assessment for HD (PBA-HD), but 
there is no consensus on the most appropriate, reliabl  or valid measure. The only 
recommended scale from the existing literature is the Irritability Scale, which despite having 
high internal consistency has only moderate interra reliability and so far little evidence of 
convergent validity (Mestre et al., 2016). Furthermo e, the lack of a core and widely-
understood construct means that different measures pot ntially measure different constructs. 
This can result in inconsistencies in research findings based on the choice of measure, as 
opposed to true differences between cohorts. It may also be important to consider whether a 
single measure of irritability is able to provide an ccurate depiction of irritability (Klöppel et 
al., 2010).   
Furthermore, irritability measures can rely on eithr self-report, caregiver-report, 
clinician-based assessment and in some cases a combination of the three, and it cannot be 
assumed that these are comparable given that differenc s have been highlighted between e.g. 
self- and informant-report, with self-report increasingly diverging from informant-report as 
the disease progresses (Chatterjee et al., 2005; Reedek r et al., 2012). Family- and clinician-
rated measures are limited in that ratings can onlybe based on observable behaviour (Bogart, 
2011). Self-report measures like the SIS are therefore important to measure the individuals’ 
experience (e.g. of ‘inward irritability’), and if irritability can be conceptualised as a 
“temporary psychological state” (Snaith et al., 1978, p.164) then self-report measures can 
play a pivotal role in the assessment process (Holtzman et al., 2015). However, self-report 
measures may become increasingly unsuitable as the disease progresses and self-awareness 
of mood or personality becomes more impaired, and more emphasis on objective or 
interviewer-rated measures may become appropriate, supplemented with clinician 


















al., 2002b). Measures such as the PBA-HD, which are conducted with the person with HD, a 
spouse or carer and additionally acknowledge interviewer observations (Callaghan et al., 
2015; Craufurd et al., 2001), may be the best choices for holistic assessment.  
Additionally, the lack of agreed definition may mean that individual participants have 
different understandings of irritability (Klöppel et al., 2010). Therefore, people’s experience 
and understanding of what irritability comprises is likely to differ, as will the behaviours 
people attribute to irritability. For example, some people with HD may understand anger and 
aggression as a consequence of irritability whereas others may not. Such subjectivity is 
certain to affect the validity of both self- and informant-reported measures. 
Indeed, it seems apparent that it is difficult to determine whether irritability is a 
separate construct from others such as anger, aggression and agitation. For example, Paulsen 
et al. (2001) found a high correlation between irritability and agitation (r = 0.81), suggesting 
the same construct was being measured and so irritability may not be a valid independent 
symptom (as it is currently considered). Alternatively, they may comprise associated 
constructs; Siemer’s (2009) dispositional theory of m ods assumes that moods dispose 
people to appraise events/situations in an emotionally congruent manner. It may therefore be 
suggested that irritability predisposes an individual to become angry or make angry 
appraisals, consistent with how they are currently feeling. The theoretical difficulty in 
discriminating between irritability and anger becomes even more difficult when measurement 
problems are taken into account; for example, the NPI was used in several studies in the 
current review (Litvan et al., 1998; Paulsen et al., 2001; Ruiz-Idiago et al., 2017), in which 
the item for irritability is ‘does the patient have sudden flashes of anger’ (Cummings et al., 
1994). Therefore, in Paulsen et al.’s (2001) study, a positive correlation between agitation 


















Additionally, irritability has been shown to correlate positively with anxiety (Litvan et 
al., 1998; Paulsen et al., 2001) and depression (Litvan et al., 1998; Nimmagadda et al., 2011).  
The findings indicate the potential for irritability o result from feelings of anxiety and 
depression or vice versa, as opposed to it being an independent construct. Certainly 
irritability research in young people have suggested that higher levels of irritability predict 
aggression, anxiety and depression in early adulthood (Leibenluft & Stoddard, 2013), 
suggesting an important association (although without determining its nature).     
In contrast to this hypothesis, a factor analysis of the PBA-HD showed irritability to 
be an independent factor (Craufurd et al., 2001). However, aggression was located within this 
factor; this may again suggest that these two construct  are not independent and that 
aggression occurs as part of irritability, potentially s an external expression. Furthermore, it 
has been suggested that irritability be “viewed as a decreased threshold for experiencing 
frustration” (Deveney et al., 2013, p.1187). As irritability is often elicited through tasks 
which induce frustration, it is possible that irritability is the expression of multiple 
frustrations, which are likely to differ between peo le. Consequently, irritability may result 
from people struggling to regulate their emotions ad behavioural responses; if frustrations 
become too much, anger and aggression follow (Zarotti, Fletcher & Simpson, 2018; Zarotti, 
Simpson, Fletcher, Squitieri & Migliore, 2018). 
Additionally, from the research reviewed here, the concept of irritability has very 
limited predictive validity. It modestly predicted suicidal ideation in two studies (Honrath et 
al., 2018; van Duijin et al., 2018), although in Honrath et al.’s study this only applied to 
manifest (not premanifest) groups. Otherwise, no predictive value was reported. In addition, 
of the 12 papers that investigated irritability across disease stage, eight did not find a 


















majority therefore suggesting that irritability may not follow the disease course. Where 
changes in irritability were found, these still did not follow the course of degeneration, while 
other emotional difficulties such as apathy did (Kingma et al., 2008).. Equally importantly, 
this lack of consensus highlights the aforementioned difficulties incurred due to heterogeneity 
between study methodologies, measurement tools and definitions of irritability. At present, 
outcomes of studies of irritability in people with HD are affected by measures used, how 




 Future research should consider how irritability is understood in the context of HD.  
This may include further investigation into the neural pathways and circuitry associated with 
irritability and considering whether areas are, in fact, related to irritability or other 
potentially-associated constructs such as anger. Furthermore, consensus should be sought 
regarding the measures used to assess irritability in people with HD and their clinical cut-
offs, particularly in relation to early-stage HD as earlier identification may help to mitigate 
the effects of irritability on maintenance of employment and the social/relational aspects of 
daily life (Sobreira, Ferreira & Alves, 2016). A number of psychological interventions are 
well-known to be effective for those with anger and aggression (see Glancy & Saini, 2005, 
for a review) and these might be appropriate for thse with HD who are considered to 
experience irritability. 
  For irritability to be clinically meaningful, it will also be essential to disambiguate 
what is meant by the term, what this means in context of HD specifically, and whether 
different measures do actually assess this construct o  variations of it. Finally, cross-cultural 


















country, China (Yang et al., 2016), and it cannot be assumed that Western-based study 
findings generalise across cultures. 
Conclusions 
 
Considering the available literature, no satisfactory definition of irritability within the 
context of HD currently exists. Indeed, considering the correlates of irritability, including 
depression, apathy and anxiety, these may currently provide more meaningful information 
about a person’s experience. Additionally, current treatment options appear designed to treat 
these associated psychological difficulties rather an specifically targeting irritability. 
Furthermore, the research remains unclear both in terms of the biological nature and 
aetiology of irritability, its associations with other psychological and emotional difficulties, 
and its relation to similar constructs (e.g. how a person feels when irritable may lead to the 
overt expression of irritability as anger). Therefo, measures need to capture the associated 
behavioural, cognitive and affective dimensions (Eckhardt, Norlander & Deffenbacher, 
2004).   
The evidence presented makes it difficult to conclude whether irritability in people 
with HD is a valid concept, with conflicting results being found. Such investigation does not, 
however, exclude or cast doubt on the reality of what we are describing as irritability for 
many individuals affected by HD and their clinicians. It does, however, suggest that if we are 
to provide effective help, we need to be much clearer on all aspects of this often extremely 
distressing experience.   
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Summary of studies of irritability in people with HD  
Citation Participants (N) Gender (N) Age (Mean) HD stage Irritability 
measures 
Other measures 
Anderson et al. 
(2016)  
Mutation carriers (270) 
Non carriers (531) 
Female (559) 
Male (242) 
45 Various  UHDRS-b BDI; BHS; BIS; 
UHDRS-m 




- 47.7 - UHDRS-b HAM-D 
Berrios et al. (2001) HD (26) Female (10) 
Male (16) 
37.8 Various IRR PER, BDI, CFQ, 
SIGNAL, MOC, 
DIS, STAI & 
STAI2 
Berrios et al. (2002) Gene carriers (32) 
Non carriers (66) 
Female (56) 
Male (42) 
46.7 Asymptomatic  IRR PER, BDI, CFQ, 
SIGNAL, MOC, 
DIS 
Bouwens et al. 
(2016) 
Mutation carriers (124) 












Bouwens et al. 
(2015) 



















for this research) 
Yudofsky 
Aggression Scale  
Chatterjee et al. 
(2005) 










Craufurd et al. 
(2001) 
Gene carriers (134) Female (71) 
Male (63) 


















Citation Participants (N) Gender (N) Age (Mean) HD stage Irritability 
measures 
Other measures 




PHD: female (15); male 
(8) 
EHD: female (9); male 
(14) 





PHD (23)  
EHD (15) 
 
Irritability Scale UHDRS, PSQI, 
ESS, HADS 
Fritz et al. (2018) PHD (193) 
EHD (187) 
LHD (91) 
PHD: female (125); 
male (68) 
EHD: female (104); 
male (83) 
























Groves et al. (2011) Physician leaders from 
HD (55) speciality 
centres (55) 
- - - - - 
Honrath et al. (2018) PHD (1220) 
MHD (4489) 
PHD: female (764); 
male (456) 







Hubers et al. (2013) Gene carriers (2106 at 




50.3 Motor symptomatic  UHDRS-b - 
Julien et al. (2007) Gene carriers (89) 
Non carriers (115) 
Female (123) 
Male (81) 
38 - CIDI - 
Kingma et al. (2008) Non-carriers (56) 

































Kirkwood et al. 
(2002a) 










Kirkwood et al. 
(2002b)                                    
HD (175) 





Manifest HD (26) 
Abbreviated MMPI 
Irritability scale 
(content analysis of 
MMPI items) 
- 
Klöppel et al. (2010) Gene carriers (16) 















- HD: 43.8  
PSP: 66.6  
Various stages NPI UHDRS 
Maltby et al. (2016) Gene carriers (1264) Female: 667 
Male: 597 
48.7 Premanifest to Stage 
V 
SIS UHDRS 
Martinez-Horta et al. 
(2016) 
PHD far from onset 
(34) 
PHD near onset (24) 
EHD (70) 
Non-carriers (101) 
PHD far from onset: 
female (22); male 12 
PHD near onset: female 
(12), male (13) 
EHD: female (41), male 
(29) 
Non-carriers: female 
(67), male (34) 
PHD far from onset: 34.8 
PHD near onset: 40.4 
EHD: 47.2 
Non-carriers: 43.3 
PHD judged 10.8< 
years from onset 
(34) 
PHD judged ≤10.8 




Nimmagadda et al. 
(2011) 






























Citation Participants (N) Gender (N) Age (Mean) HD stage Irritability 
measures 
Other measures 
Caregivers (52) Male (25) 












Reedeker et al. 
(2012) 
Gene carriers (130)  
Non carriers (43) 
Informants (158) 





Rickards et al. 
(2010) 
People with HD (1690) - - - UHDRS-b - 
Ruiz-Idiago et al. 
(2017) 





Control: no family 
history of HD (13) 
At risk: female (3), 
male (6) 
PMD: female (10), 
male (2) 
MHD: female (39), 
male (38) 
Control: expansion 
negative: female (3), 
male (3) 
Control: no history: 
female (11), male (2) 





Control: no family history 
of HD: 61.0 








Singh-Bains et al. 
(2016) 
People with HD (8) 
Matched healthy 
controls (7) 
HD: male (6); female 
(2) 




Deceased IDAS QNE 
MMSE  
HADS 
Thompson et al. 
(2002) 
People with HD (82) Female (41) 
Male (41) 











48 Clinically diagnosed 
HD 
PBA-HD - 


















Citation Participants (N) Gender (N) Age (Mean) HD stage Irritability 
measures 
Other measures 
(2016) Male (687) between stages I-III SF-36 
van den Stock et al. 
(2015) 
Gene carriers (20)  
Non-carriers (20)  
Female (23) 
Male (17) 
37.5 Pre-manifest PBA-HD UHDRS 
BDI 
STAI 
van Duijn. (2010) Review of treatment 
studies 
- - - - - 
van Duijn et al. 
(2013) 
HD (121) - - Pre-symptomatic = 
46 
Symptomatic = 75 
PBA - 
van Duijn et al. 
(2014) 
Gene carriers (1993) Female (977) 
Male (1016) 
50.3 Early and mid-stage UHDRS-b - 
van Duijn et al. 
(2018) 
Gene carriers (1451) Female (795) 
Male (656) 









Vassos, Panas, Kladi 
& Vassilopoulos 
(2007) 








Yang et al. (2016) HD patients (58) Female (33) 
Male (25) 




Abbreviations: AD = Alzheimer’s disease; BADS = Behavioural Assessment of Dysexecutive Syndrome; BDI = Beck Depression Inventory; BHS = Beck 
Hopelessness Scale; BIS/BIS11 = Barratt Impulsiveness Scale; CFQ = Cognitive Failures Questionnaire; CIDI = Composite International Diagnostic 
Interview; C-SSRS = Columbia Suicide Severity Rating Scale; DIS = Dissociation Questionnaire; EHD: early-stage Huntington’s disease; ESS = Epworth 


















Hamilton Depression Rating Scale; HDHQ = Hostility & Direction of Hostility Questionnaire; HDQLIFE = Huntington Disease Quality of Life; HRQOL = 
health-related quality of life; IDAS = Irritability, Depression, and Anxiety Scale; IRR = Snaith’s Irritability Scale; IS = Irritability Scale; LHD = late-stage 
Huntington’s disease; MADRS = Montgomery & Asberg Depression Rating Scale; MHD: manifest Huntington’s disease; MMPI = Minnesota Multiphasic 
Personality Inventory; MMSE = Mini-Mental State Exam; MOC = Maudsley Obsessive-Compulsive Questionnaire; Neuro-QOL = Quality of Life in 
Neurological Disorders; NL-PBA = Problem Behaviours Assessment – Dutch translation; NPI = Neuropsychiatric Inventory; PBA = Problem Behaviours 
Assessment; PBA-s = Problem Behaviours Assessment – short form; PER = Personality Deviance Scale; PMD = premanifest HD; PROMIS = Patient 
Reported Outcomes Measurement Information System; PSQI = Pittsburgh Sleep Quality Index; QNE = Quantified Neurological Examination; SF-36 = 
Medical Outcome Study 36-Item Short Form Health Survey; SIGNAL = Signal Detection Memory Test; SIS = Snaith Irritability Self-Assessment Scale; 
STAI & STAI2 = Spielberger Anxiety scales; UHDRS = Unified Huntington’s Disease Rating Scale (-b = behaviour component; -m = motor component); 




















Results of studies of irritability in people with HD 
Citation Aim Results related to irritability 
Anderson et al. 
(2016) 
Identify associations between 
neuropsychiatric symptoms 
and suicidal ideation. 
No significant difference in suicidal ideation betwen gene carriers and non-carriers (p = .2275), and 
gene mutation presence did not significantly increase the chance of the participant reporting suicidal 
ideation.  For gene carriers, only hopelessness significantly predicted suicidal ideation (for non-carrie s, 
hopelessness, irritability and anxiety were all signif cantly predictive of suicidal ideation). 
Banaszkiewicz 
et al. (2012) 
Identify determinants of 
quality of life, functional 
disability and caregiver 
burden.  
Irritability is not significantly associated with disability.  
Berrios et al. 
(2001) 
Investigate the relationship 
between psychiatric profile 
and CAG repeats.  
Compared with available norms, participants showed increased levels of ‘outward irritability’. No 
significant correlation with irritability and CAG repeat length.  
Berrios et al. 
(2002) 
Compare psychiatric profiles 
of gene carriers and non-
carriers.   
Significant difference in inward and outward irritability between GC and NGC, with irritability being 
higher in GC.  Factor structure: inward and outward irritability were included within the ‘personality’ 
factor.  
Bouwens et al. 
(2016) 
Identify whether cytokine 
levels are associated with 
neuropsychiatric symptoms 
and cognitive dysfunction. 
Plasma cytokine levels were inversely associated with executive functioning (IL-6: β = -0.114; p = .01) 
(IL-1ra: β = -0.110; p = .02), but not with any other neuropsychiatric symptom score including 
irritability. 
Bouwens et al. 
(2015) 
Investigate the course and 
temporal relationship between 
irritability and other 
psychological difficulties.   
No significant increase in irritability from baseline to follow-up. At baseline 33% of people with HD 
were irritable, with 70% of those remaining irritable at 2-year follow-up. Of those who were not 
irritable at baseline 23% developed irritability at 2-year follow-up. Multivariate regression model 
showed an association between increase in apathy and an increase in irritability, when including 
confounds such as age, sex, motor function changes and medication use. Continuous use of 
antipsychotics associated with an increase in irritabili y.  
Burns et al. 
(1990) 
Compare irritability, 
aggression and apathy in 
people with HD with people 
with AD.  
No significant difference in irritability or apathy between the HD and AD groups. HD group were 
significantly more aggressive than the AD group andggressive outbursts lasted longer in the HD 
group.  Irritability, apathy & aggression were independent of each other in both groups. Irritability 
correlated positively with bad temper in the HD group but there was no correlation in the AD group.     


















Citation Aim Results related to irritability 
(2005) people with HD and their 
caregivers regarding presence 
of irritability, apathy and 
depression.  
scores. Difference in apathy scores between the two groups.   
Craufurd et al. 
(2001) 
Understand behavioural 
abnormalities in people with 
HD and develop a method of 
assessing these changes.  
Irritability present in 44% of sample (severity rating of 2 or more). Three factors obtained from factor 
analysis: 1 - apathy; 2 - irritability; 3 - depression.  Irritability difficulties occurred more frequently in 
people with HD with an illness duration of 6-11 years.  Irritability factor showed no correlation with 
duration of illness or CAG repeat length.  
Diago et al. 
(2018) 
Investigate relationships 
between sleep quality and 
psychological factors in 
people with HD. 
Irritability non-significantly higher in comparisons between controls and premanifest HD (mean 
difference: 1.65; p = .330) and early-stage HD (mean difference: 2.00; p = .412). No significant 
correlation between sleep quality (rho = .368; p = .023), sleep latency (rho = .224; p = .177), sleep 
disturbance (rho = .321, p = .0050), sleep dysfunctio  (rho = .193, p = .247) or sleepiness (rho = .277, p 
= .092). 
Fritz et al. 
(2018) 
Examine relationships 
between apathy and 
behaviour, cognition, physical 
function and health-related 
quality of life in people with 
HD. 
Better clinician-reported behavioural scores (including irritability) associated with better apathy scores 
(p<.001, adjusted R2 = .30 (large effect size)). Smaller (moderate) R2 found for physical ability, 
functioning and cognition. 
Gregory et al 
(2015) 
Investigate structural 
connectivity and changes 
associated with depression, 
apathy and irritability in HD.  
Significant difference in irritability between the two groups. Significant negative correlations between 
irritability score and fractional anisotropy which was dependent on cumulative probability to onset.  
Groves et al. 
(2011) 
Provide direction for the 
management of irritability in 
people with HD. 
SSRIs were most frequently used to treat mild to moderate irritability in HD. Antipsychotics (APD) 
were more commonly used in Europe to treat mild to moderate irritability than in North America & 
Australia.  SSRIs used when irritability occurred with comorbid depression and anxiety. APDs used 
when irritability occurred with aggression and impulsivity.  
Honrath et al. 
(2018) 
Assess neuropsychological 
risk factors for suicidal 
ideation. 
Irritability was not associated with suicidal ideation in the premanifest group, but was a significant 
predictor of suicidal ideation for the manifest group (B = 0.039; SE = 0.012; OR = 1.040, [CI = 1.016-
1.064], p = .001). 
Hubers et al. 
(2013) 
Investigates predictors and 
correlates of suicidal ideation 
in people with HD.  
Baseline presence of irritability significantly correlated with suicidal ideation – those with suicidal 
ideation were more irritable than those without. Multivariate analyses indicated irritability was not an


















Citation Aim Results related to irritability 
ideation in people with HD. 
Julien et al. 
(2007) 
Compare the prevalence of 
psychological difficulties in 
pre-symptomatic gene carriers 
and non-carriers and to look at 
the relationship with 
proximity to onset.  
Gene carriers reported a greater prevalence of ‘manic’ symptoms (11%) compared with NGC (4%) – in 
every case irritability was reported. Irritability was increased in gene carriers up to 10 years prior to 
clinical onset but not in those further from onset. No significant relationship between proximity to 
onset and irritability within the 10 year period.     
Kingma et al. 
(2008) 
Investigate behavioural 
difficulties in people with HD.  
Factor analysis revealed 3 components: irritability, apathy and depression. All mutation carriers 
showed significantly more irritability, apathy & depr ssion than non-carriers. No significant differenc  
in irritability between advanced symptomatic GCs and other disease stages. No significant relationship 
between irritability and depression or apathy.   
Kirkwood et al. 
(2002a) 
Examine whether longitudinal 
changes in personality can be 
detected in pre-symptomatic 
gene carriers. 
Greater increase irritability and clinical hostility observed over time in the pre-symptomatic GC group 
compared with NGC. No correlation between number of CAG repeats and irritability in both groups.   
Kirkwood et al. 
(2002b)                                                
Investigate whether 
psychological difficulties can 
be detected in pre-
symptomatic HD.  
No significant difference in MMPI scores across groups. No significant difference in irritability across 
the three groups and no association with proximity to onset.  
Klöppel et al. 
(2010) 
Examine the emotional 
neurocircuitry associated with 
irritation,  
No significant difference in irritability between pre-symptomatic GCs and controls. Companions’ 
ratings did not differ from those of the pre-symptomatic GCs. Ratings on the SIS were within the 
normal range, apart from 1 pre-symptomatic GC. Negative emotions positively correlated with SIS & 
BIS-11.   
Litvan et al. 
(1998) 
Compare neuropsychiatric 
aspects of HD compared with 
PSP.  
Irritability influenced the total NPI score in PwHD. PwHD scored significantly higher on agitation, 
irritability and anxiety while those with PSP scored higher for apathy. In PwHD, agitation was 
correlated with anxiety, irritability, disinhibition and euphoria. Irritability was associated with anxiety, 
disinhibition, euphoria and depression. Logistic regression analysis indicated PwHD are more likely to 
exhibit hyperactive behaviour. People with PSP are more likely to exhibit hypoactive behaviour.     
Maltby et al. 
(2016) 
Analyse the factor structure of 
the irritability construct as 
reported via the SIS. 
Confirmatory factor analysis found two bifactor models to offer the best fit of the data, both comprising 
a general irritability factor and two group factors: 1) outward irritability and inward irritability, as per 
the original conceptualisation of the SIS (general factor explained 64.2% of variance; inward irritability 
13.7%; outward irritability 22.1%); 2) temper and self-harm, as generated by exploratory factor 


















Citation Aim Results related to irritability 
higher on the general factor for both models. Recommendation is that the full scale score be used as an 
overall measure of irritability. 
Martinez-Horta 
et al. (2016) 
Explore relationships between 
neuropsychiatric symptoms 
and disease stage/controls, as 
well as medication use. 
In the far from onset group, irritability was the most prevalent symptom (32%) along with depression 
(no increased risk of irritability by odds ratio). In the close to onset group, irritability (56%) was the 
second-most prevalent symptom after apathy (64%), with OR: 5.1. In the early-stage HD group, 
irritability was the third most prevalent symptom (47%) after depression (65%) and apathy (63%), with 
OR: 3.6. In the non-carrier controls, irritability was present in 20%. Significant difference on irritab lity 
prevalence between groups (p < .001); close to onset and early-stage HD had higher mean irritability 
than people far from onset and non-carrier controls. Strong correlation between irritability and use of 




Investigate the association of 
irritability in people with HD 
with other psychological 
constructs and movement 
disorder.  
Both inward and outward irritability were significantly positively associated with MADRS scores, 
STAI state and trait anxiety scores. BIS scores were positively associated with STAI trait scores and 
both outward and inward irritability scores on the IDA. Negative correlation between irritability scores 
and the UHDRS.  
 
Paulsen et al. 
(2001) 
Use the NPI to characterise 
neuropsychiatric symptoms in 
people with HD.  
Irritability endorsed in 65.4% of sample. NPI. High correlation between irritability & agitation 
indicating two scales are measuring the same construct. I ritability also correlated with anxiety and 
disinhibition.  
Pflanz et al. 
(1991) 
Determine the range and 
frequency of psychological 
difficulties in people with HD.  
Irritability present in 64% of cases and was the 2nd most common difficulty. Irritability occurred 
between 0-3 years prior to onset of motor symptoms. Lo s of interest and concentration correlated with
irritability.   
Reedeker et al. 
(2012) 
Investigate the psychometric 
properties of the Irritability 
Scale against the PBA 
irritability factor to establish a 
reliable cut off.  
Irritability significantly higher in mutation carriers (35% irritable) than NC (9% irritable). 28% of 
mutation carriers considered irritable according to IS-self and informant scales. 50% considered not 
irritable according to both scales. For the remaining 23% there was disagreement between participants 
and informants (18/27 reported selves as not irritable but their informant did). Irritability independently 
correlated with benzodiazepine use.  
Rickards et al. 
(2010) 
Perform a factor analysis on 
completed UHDRS-b 
assessments.   
Factor analysis indicated that irritability is a distinct ‘psychiatric symptom’ in HD.  
Ruiz-Idiago et 
al. (2017) 
To validate the Spanish PBA-s 
including internal consistency, 
inter- and intra-rater 
Internal consistency was good (Cronbach’s α = .79) and NPI items assessing similar symptoms 
correlated strongly (for irritability, r = .918, p<.01). Inter- and intra-rater reliability were good (Cohen’s 


















Citation Aim Results related to irritability 
reliability, exploratory factor 
analysis and convergent 
validity. 
rater); .91-.93 (inter-rater)). A four-factor model accounted for 56% of the variance in outcomes, 
comprising irritability (18%), apathy (13%), depression (15%) and perseveration (10%); the irritability 
factor comprised items relating to irritability and aggressiveness. Irritability did not correlate with 
UHDRS Total Functional Change outcomes (r = .050, p = .597). 
Singh-Bains et 
al. (2016) 
Relate neurodegeneration in 
the globus pallidus to clinical 
symptomatology. 
Relative to controls, in HD patients the external globus pallidus showed a 54% overall volume decline, 
60% neuron loss and 34% reduced soma volume. The ventral pallidum was similarly affected, with a 
31% reduction in volume, 48% neuron loss and 64% reduc d soma volume. The internal globus 
pallidus was less affected (38% loss of overall volume only, without concurrent neuronal loss. Volume 
loss was greater at later stages of disease for all three subdivisions of the global pallidus. Decreasing 
internal globus pallidus volume was associated withdecreasing irritability (rs = 0.90; p = .04). 
Decreasing volume in the external globus pallidus and ventral pallidus was not associated with 
irritability (rs = .50; p = .23 in both cases), but was associated with increasing cognitive and motor 
impairment. Increasing years since symptom onset was also associated with decreased irritability (rs = -
.90; p = .04). 
Thompson et al. 
(2002) 
Investigate how behavioural 
change in people with HD 
relates to other indices of 
disease severity. 
Depression & irritability subscales poorly correlatd with functional capacity, motor impairment & 
cognition. Apathy was significantly correlated. UHDRS-b score significantly correlated with PBA-HD 
depression & irritability subscales. UHDRS irritability scale significantly correlated with irritability 
subscale of the PBA-HD.   
Thompson et al. 
(2012) 
Evaluate the prevalence of 
neuropsychiatric difficulties in 
people with HD over time.  
Irritability common with a prevalence ranging from 49-83%. Longitudinal analysis showed an increase 
in irritability over time with a significant linear effect in those who entered the study at stage I and II 




indicators of pain in people 
with HD. 
Interviewed-rated irritability was a significant predictor of pain severity (OR: 1.053, p = .002) after 
controlling for confounds (gender, age, disease stage, motor function and dementia). Higher 
participant-rated irritability score was not associated with an increase in the odds of greater pain 
severity (OR: 1.095, p = .056). 
van den Stock et 
al. (2015) 
Identify structural and 
functional brain changes 
underlying irritability in pre-
manifest HD.  
Irritability significantly higher in GC vs NC. 
van Duijn. 
(2010) 
Review the treatments of 
irritability.  
Suggests use of an SSRI as a first-choice medication to manage irritability in people with HD or a 
mood stabiliser.  An alternative would be an antipsychotic. Behavioural or other psychotherapeutic 
interventions should be considered.    


















Citation Aim Results related to irritability 
(2013) irritability, depression and 
apathy in people with HD over 
a 2-year follow up.  
UHDRS-m: as UHDRS-m score increased so did the PBA irritability factor. In pre-symptomatic group, 
strongest relationship was between an increased UHDRS-m score and increased irritability score.  At 
follow-up 15 of the pre-symptomatic group were symptomatic. No significant increase in irritability 
compared with those who remained pre-symptomatic.  
van Duijn et al. 
(2014) 
Examine occurrence and 
correlates of neuropsychiatric 
symptoms in people with HD. 
61.4% of HD mutation carriers scored ‘no irritability’, 24.7% scored ‘mild irritability’ and 13.9% 
scored ‘moderate/severe irritability’. The prevalenc  of moderate/ severe irritability increased by stage 
of disease from 10.4% at stage 1 to 19.6% at stages 4-5. Irritability independently correlated with male 
sex, younger age, a history of depression, psychosis and a previous suicide attempt.   
van Duijn et al. 
(2018) 
Examine correlates of suicidal 
ideation and suicidal 
behaviour in gene carriers. 
HD gene carriers with moderate/severe irritability had significantly higher mean suicidal ideation score 
(0.83, SE 0.09) and suicidal behaviour score (0.24, SE 0.04) than those with no or mild irritability. 
Moderate/severe irritability significantly predicted suicidal ideation (b = 0.068, p - .01) and suicidal 
behaviour (b = 0.071, p - .01). Those with mild and no irritability differed only in passive suicidal 
ideation (higher for mild irritability, p < .001). Suicide attempts had occurred more frequently in those 
with moderate/severe irritability (10.4%) than those with no (5.6%) or mild (5.7%) irritability. There 
were no significant between-group differences for self-injurious behaviour. The correlation between 






Distinguish which behavioural 
and psychiatric features 
differentiate gene carriers with 
non-carriers.   
No significant difference in irritability between GC and NC. Higher extroverted hostility in GC than in 
NC. Overlap between the two groups suggests extrover ed hostility may not be pathologic in GC. 
Yang et al. 
(2016) 
Identify relationships between 
CAG repeats, age of onset and 
irritability in Chinese 
clinically-diagnosed HD 
patients. 
Irritability was positively correlated with CAG repats (r = .449; p < .001) and negatively correlated 
with age of onset (r = -.391, p = .002). There was no ignificant difference in prevalence (p = .300) or 
scores (p = .403) of behaviour symptoms between males and females. 
 
Abbreviations: AD = Alzheimer’s disease; BDI = Beck Depression Inventory; BIS/BIS11 = Barratt Impulsiveness Scale; GC = gene carriers; HD = 
Huntington’s disease; IDAS = Irritability, Depression, and Anxiety Scale; MADRS = Montgomery & Asberg Depression Rating Scale; MMPI = Minnesota 
Multiphasic Personality Inventory; NGC = non-gene carriers; NPI = Neuropsychiatric Inventory; OR = odds ratio; PBA = Problem Behaviours Assessment; 






































Measures of irritability in HD 
Measure Description Reliability Validity 
Burns Irritability Scale (BIS; 
Burns, Folstein, Brandt & 
Folstein, 1990) 
Measures irritability and 
apathy according to carer’s 
ratings and does not include 
subjective experience. It uses 
a 5-point scale assessing the 
presence of irritability 
ranging from “never” to 
“always”.  
Internal consistency: 
- Irritability: α = 0.82 
- Apathy: α = 0.78 
Inter-rater1: 
- Whole interview: κ = 0.98 
- Irritability:  κ = 1.00 
- Apathy: κ = 0.85 
Test-retest: 
- Whole interview: κ = 0.88 
- Irritability: κ = 0.81 
- Apathy: κ = 0.76 
Convergent: 
- Psychogeriatric Dependency 
Rating Scale: r = 0.87 
Irritability, depression, 
anxiety scale (IDA; Snaith, 
Constantopoulos, Jardine & 
McGuffin 1978) 
Scale assessing irritability, 
depression and anxiety to be 
used within clinical context.  
Irritability understood as a 
temporary psychological 
state. Includes 8 irritability 
items 
Inter-rater: 
- Outward irritability: r = .87-.90 
- Inward irritability: r = .74-.90 
- Depression: r = .80-.90 
- Anxiety: r = .75-.80 
Split-half:  
- Outward irritability: r = .77, .80, 
.88 
- Inward irritability: r = .70, .92, .93 
- Depression: r = .72, .77, .81 
- Anxiety: r = .74, .80, .87 
 
Irritability Questionnaire 
(IRQ; Craig, Hietenan, 
Markova & Berrios, 2008) 
Subjective measure of 
irritability. Consists of 21 
items assessing the frequency 
and severity of irritability 
with each individual item 
Internal consistency: 
- Global: α = 0.90 
             Split half = 0.78 
- Frequency: α = 0.90 
                   Split half = 0.77 
Convergent: 
- Trait anger scale: r = 0.72 
- State anger scale: r = 0.58 
- IDA outward: r = 0.58 
- IDA inward: r = 0.49 
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Measure Description Reliability Validity 
score ranging from 0-3.   - Severity: α = 0.89 
                Split half = 0.58 
Retest reliability: r = 0.82 
- BIS: r = 0.37 
  
John Hopkins Irritability 
Scale (Chatterjee, Anderson, 




irritability. Consists of 14 
items pertaining to irritability 
with the range of all possible 
scores being 0-42 to assess 
the presence of irritability.  
No data available No data available 
Problem Behaviours 
Assessment – Huntington’s 
disease (PBA-HD; Craufurd, 
Thompson & Snowden, 2001) 
Semi-structured interview 
measuring behavioural 
difficulties in HD including 
the presence, severity and 
frequency. 
Inter-rater:  
- Severity: r = 0.86 
- Frequency: r = 0.84 
Internal consistency: α = 0.67 
Test-retest:  
- Severity: r = 0.94 
- Frequency: r = 0.92 
 
Unified Huntington’s Disease 
Rating Scale (UHDRS; 
Huntington Study Group, 
1996) 
Assesses difficulties in motor, 
cognitive, functional and 
behavioural domains. The 
behavioural section measures 
the frequency and severity of 
difficulties related to affect, 
thought content and coping 
styles. 
Internal Consistency: 
- Behavioural: α = 0.83 
- Motor: α = 0.95 
- Cognitive: α = 0.90 
- Functional: α = 0.95 
Divergent (Behavioural Total): 
- Motor: r = -0.10 

























































































Records remaining after 
limiting to peer-reviewed 
English language articles, and 
removal of duplicates  
(n = 232) 
Records excluded 
(n = 182) 
Records screened 
by title and 
abstract  




(n = 10) 




information on irritability 
construct: 1 
Review/commentary: 4 
Full text articles 
assessed for 
eligibility  
(n = 50) 
Studies included 
in review 




(n = 50) 
Web of 
Science  
(n = 100) 
CINAHL 
(n = 12) 
Scopus   
(n = 213) 
Records excluded 
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